Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
|Videos|June 11, 2021
New insight into axial length, data shows
Advertisement
Emmetropes show axial length growth just like their myopic counterparts, says Paul Chamberlain, director of
Advertisement
Related to this article
Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5